Plasma Cell And B Cell-Targeted Treatments For Use In Advanced Multiple Sclerosis

Publication date: Available online 26 June 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): David Baker, Benjamin M. Jacobs, Sharmilee Gnanapavan, Klaus Schmierer, Gavin GiovannoniABSTRACTThere is increasing evidence that agents that target peripheral B cells and in some instances plasma cells can exhibit marked effects on relapsing multiple sclerosis. In addition, B cells, including plasma cells, within the central nervous system compartment are likely to play an important role in disease progression in both relapsing and progressive MS. However, current B cell-targeting antibodies may not inhibit these, because of poor penetration into the central nervous system and often oligoclonal bands of immunoglobulin persist within the cerebrospinal fluid despite immunotherapy. Through targeting B cells and plasma cells in the CNS, it may be possible to obtain additional benefit above simple peripheral depletion of B cells. As such there are a number of inhibitors of B cell function and B cell depleting agents that have been developed for myeloma and B cell leukaemia and lymphoma, which could potentially be used off-label or as an experimental treatment for advanced (progressive) MS.

Source: Multiple Sclerosis and Related Disorders - June 26, 2019 Category: Neurology Source Type: research